Meta-Analysis
Copyright ©The Author(s) 2016.
World J Meta-Anal. Jun 26, 2016; 4(3): 69-76
Published online Jun 26, 2016. doi: 10.13105/wjma.v4.i3.69
Figure 1
Figure 1 The details of identifying studies. RCT: Randomized controlled trials; GnRH: Gonadotropin-releasing hormone.
Figure 2
Figure 2 The effects of degarelix (240/80 mg) and goserelin (3. 6 mg) on mean percentage changes of total prostate volume and quality of life related to urinary symptoms within included studies. QoL: Quality of life.
Figure 3
Figure 3 The effects of degarelix (240/80 mg) and goserelin (3. 6 mg) on mean International Prostate Symptom Score and International Prostate Symptom Score ≥ 13 within included studies. IPSS: International Prostate Symptom Score.
Figure 4
Figure 4 The effect of degarelix (240/80 mg vs 240/160 mg) on serum testosterone and prostate-specific antigen within included studies. PSA: Prostate-specific antigen.